Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orladeyo
Pharma
In competitive HAE market, CSL gains FDA approval for Andembry
With the FDA's approval of hereditary angioedema treatment Andembry, CSL is ready to take on Takeda’s blockbuster Takhzyro and BioCryst's Orladeyo.
Kevin Dunleavy
Jun 17, 2025 11:10am
New HAE drugs from Takeda, BioCryst are gaining popularity
Mar 18, 2022 11:16am
Sinopharm, Sinovac, Astellas, BGI and more—Fierce Pharma Asia
Jul 16, 2021 8:50am
Can durability data keep Takeda's Takhzyro in control in HAE?
Jul 12, 2021 12:59pm
Fueled by patient insights, BioCryst's HAE launch takes flight
May 25, 2021 4:51pm
